{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:12:26Z","timestamp":1785186746358,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05747-3","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T23:01:40Z","timestamp":1713913300000},"page":"2765-2774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-0437","authenticated-orcid":false,"given":"Sara","family":"Benchikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soro Somda Georgina","family":"Charl\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amale","family":"Bousfiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunda","family":"Razoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Aboulfaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifa","family":"Zarouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil El","family":"Hamouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"Nassereddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"2","key":"5747_CR1","first-page":"83","volume":"54","author":"LE Dorfman","year":"2018","unstructured":"Dorfman LE, Floriani MA, Oliveira TMRDR, Cunegatto B, Rosa RFM, Zen PRG. The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia. J Bras Patol E Med Lab. 2018;54(2):83\u201391.","journal-title":"J Bras Patol E Med Lab"},{"issue":"S2","key":"5747_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(S2):107\u201321.","journal-title":"Ann Hematol avr"},{"issue":"12","key":"5747_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s004320050228","volume":"124","author":"G Pasternak","year":"1998","unstructured":"Pasternak G, Hochhaus A, Schultheis B, Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol. 1998;124(12):643\u201360.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"5747_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(10):1385\u2013415.","journal-title":"J Natl Compr Canc Netw 1 oct"},{"key":"5747_CR5","author":"M Rohrbacher","year":"2018","unstructured":"Rohrbacher, M., Hasford, J. (2018). Epidemiology and etiology of chronic myeloid leukemia. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic diseases of the blood. Springer, Cham."},{"key":"5747_CR6","doi-asserted-by":"publisher","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","volume":"10","author":"Q Lin","year":"2020","unstructured":"Lin Q, Mao L, Shao L, Zhu L, Han Q, Zhu H, et al. Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:580759.","journal-title":"Front Oncol 15 d\u00e9c"},{"key":"5747_CR7","doi-asserted-by":"crossref","unstructured":"Ey\u00fcpo\u011flu D, Bozkurt S, Haznedaro\u011flu \u0130, B\u00fcy\u00fcka\u0131\u0131k Y, G\u00fcven D. The impact of variant philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Hematol. 2016;33(1):60\u20135.","DOI":"10.4274\/tjh.2015.0237"},{"key":"5747_CR8","doi-asserted-by":"crossref","unstructured":"Van der Plas DC, Grosveld G, Hagemeijer A. Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. Cancer Genet Cytogenet. 1991;52(2):143\u201356.","DOI":"10.1016\/0165-4608(91)90457-6"},{"key":"5747_CR9","doi-asserted-by":"crossref","unstructured":"Safaei A, Monabati A, Safavi M, Atashabparvar A, Hosseini M. Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East. Blood Res. 2018;53(1):49.","DOI":"10.5045\/br.2018.53.1.49"},{"key":"5747_CR10","doi-asserted-by":"crossref","unstructured":"Sampaio MM, Santos MLC, Marques HS, Gon\u00e7alves VL de S, Ara?jo GRL, Lopes LW, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021;12(2):69\u201394.","DOI":"10.5306\/wjco.v12.i2.69"},{"key":"5747_CR11","doi-asserted-by":"crossref","unstructured":"Narl? \u00d6zdemir Z, K?l?\u00e7aslan NA, Y?lmaz M, E\u015fkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117(1):3\u015f15.","DOI":"10.1007\/s12185-022-03446-1"},{"key":"5747_CR12","doi-asserted-by":"crossref","unstructured":"Algahtani FH, Alqahtany FS. Evaluation and characterisation of chronic myeloid leukemia and various treatments in Saudi Arabia: a retrospective study. Journal of Infection and Public Health. 2020;13(2):295\u20138.","DOI":"10.1016\/j.jiph.2019.12.006"},{"key":"5747_CR13","doi-asserted-by":"crossref","unstructured":"Al-Bahar S, Pandita R, Al-Muhannaha A, Al-Bahar E. The epidemiology of leukemia in Kuwait. Leuk Res. 1994;18(4):251\u20135.","DOI":"10.1016\/0145-2126(94)90027-2"},{"key":"5747_CR14","doi-asserted-by":"crossref","unstructured":"Massoud M, Sakr R, Kerbage F, Makdessi J, Hawi J, Nasr F, et al. Analysis of survival of CML patients in the last 15 years in Lebanon. Clin Lymphoma Myeloma Leuk. 2015;15:S36\u20137.","DOI":"10.1016\/j.clml.2015.07.075"},{"key":"5747_CR15","unstructured":"Djouadi k, et al. Approche \u00e9pid\u00e9miologique de la Leuc\u00e9mie My\u00e9lo\u00efde chronique \u00e9tude Alg\u00e9ro-Tunisienne \u00e0 propos de 1349 cas sur 05 ans (2010 \u00e0 2014). Revue Alg\u00e9rienne d\u00e9H\u2019matologie. 2017;(12):36."},{"key":"5747_CR16","doi-asserted-by":"crossref","unstructured":"Haouas H, Haouas S, Hafsia A. A retrospective study of leukemia epidemiology in Northern Tunisia. Hematology. 2011;16(3):151\u20134.","DOI":"10.1179\/102453311X12953015767374"},{"key":"5747_CR17","unstructured":"Chapman J, Goyal A, Azevedo AM. Splenomegaly. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430907\/"},{"key":"5747_CR18","doi-asserted-by":"crossref","unstructured":"Rajabto W, Angkasa YK. Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: a case report. Niger J Clin Pract. 2022;25(3):373.","DOI":"10.4103\/njcp.njcp_1401_21"},{"key":"5747_CR19","doi-asserted-by":"crossref","unstructured":"Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, et al. Prognosis in chronic myeloid leukemia: baseline factors, dynamic risk assessment and novel insights. Cells. 2023;12(13):1703.","DOI":"10.3390\/cells12131703"},{"key":"5747_CR20","doi-asserted-by":"crossref","unstructured":"Kou F, Wu L, Ren X, Yang L. Chromosome abnormalities: new insights into their clinical significance in cancer. Mol Ther - Oncolytics. 2020;17:562\u201370.","DOI":"10.1016\/j.omto.2020.05.010"},{"key":"5747_CR21","doi-asserted-by":"crossref","unstructured":"Asnafi AA, Deris Zayeri Z, Shahrabi S, Zibara K, Vosughi T. Chronic myeloid leukemia with complex karyotypes: prognosis and therapeutic approaches. J Cell Physiol. 2019;234(5):5798\u2013806.","DOI":"10.1002\/jcp.27505"},{"key":"5747_CR22","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074\u201386.","DOI":"10.1038\/s41375-020-0826-9"},{"key":"5747_CR23","doi-asserted-by":"crossref","unstructured":"Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742\u201350.","DOI":"10.1182\/blood-2016-01-690230"},{"key":"5747_CR24","doi-asserted-by":"crossref","unstructured":"Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006;106(8):1730\u20138.","DOI":"10.1002\/cncr.21797"},{"key":"5747_CR25","doi-asserted-by":"crossref","unstructured":"Ratajczak B, Przyby\u0142owicz-Chalecka A, Czerwi\u0144ska-Rybak J, Kandu\u0142a Z, Ustaszewski A, Gil L, Lewandowski K, Jarmu\u017c-Szymczak M. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure. Leuk Res. 2023;132:107349.","DOI":"10.1016\/j.leukres.2023.107349"},{"key":"5747_CR26","doi-asserted-by":"crossref","unstructured":"Alp S, Salihoglu A, Eskazan AE, Gulturk E, Ar MC, Aydin SO, et al. Imatinib for chronic myeloid leukemia patients: a single institution experience. Blood. 2011;118(21):4429.","DOI":"10.1182\/blood.V118.21.4429.4429"},{"key":"5747_CR27","doi-asserted-by":"crossref","unstructured":"Shaya J, Pettit K, Kandarpa M, Bixby D, Mercer J, Talpaz M. Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2022;22(1):17\u201323.","DOI":"10.1016\/j.clml.2021.07.001"},{"key":"5747_CR28","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004.","DOI":"10.1056\/NEJMoa022457"},{"key":"5747_CR29","doi-asserted-by":"crossref","unstructured":"H\u00f6glund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(S2):241\u20137.","DOI":"10.1007\/s00277-015-2314-2"},{"key":"5747_CR30","doi-asserted-by":"crossref","unstructured":"Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23(3):602\u20134.","DOI":"10.1038\/leu.2008.245"},{"key":"5747_CR31","doi-asserted-by":"crossref","unstructured":"Abdulkadyrov K, Lomaia E, Lazorko N, Shuvaev V, Abdulkadyrova A, Martinkevich I, et al. Crude and age-adjusted Ph+\/Bcr-Abl\u2009+\u2009chronic myeloid leukemia incidence rate in st. Petersburg and leningrad region between 2006\u20132011. Blood. 2012;120(21):4432.","DOI":"10.1182\/blood.V120.21.4432.4432"},{"key":"5747_CR32","doi-asserted-by":"crossref","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336\u201343.","DOI":"10.1038\/leu.2015.73"},{"key":"5747_CR33","doi-asserted-by":"crossref","unstructured":"Zhao Y, Wang Y, Ma S. Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology. Sci Rep. 2018;8(1):548.","DOI":"10.1038\/s41598-017-19081-4"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05747-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:06:10Z","timestamp":1722060370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05747-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5747"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05747-3","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles set out in the Declaration of Helsinki. Informed consent is waived by the Ethics committee of Pasteur Institute of Morocco.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}